Active Research Studies

These studies are underway at the MS Center at Evergreen:

Study
Stress Management

Principle Investigator
Theodore Brown, MD

Brief Description
12 month study of 2 types of cognitive based therapy. Primary outcome MRI activity. 3T MRI every 2 months.

For more information, please contact Study Coordinator
Cynthia Lotane
425-899-5368

Study
Duloxetine

Principle Investigator
Theodore Brown, MD

Brief Description
A randomized placebo controlled trial of Duloxetine for central pain in multiple sclerosis.

Study Medication Information
Cymbalta (duloxetine) is an antidepressant medication. In addition to antidepressant effects, it also has pain relieving effects. This study will investigate the effectiveness of Cymbalta in relieving pain due to MS.

For more information, please contact Study Coordinator
Shalom Kilcup
425-899-5369
sekilcup@evergreenhealthcare.org

Principle Investigator
Theodore Brown, MD

Brief Description
To evaluate the safety and efficacy of 2 dose levels of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment.

Study Medication Information
BOTOX® (Botulinum Toxin, Type A) Purified Neurotoxin Complex will be the active study formulation (9060X)

For more information, please contact Study Coordinator
Jennifer McAleenan
425-899-5371
jkmcaleenan@evergreenhealthcare.org

Study
Nerispirdine

Principle Investigator
Theodore Brown, MD

Brief Description
Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine in Patients with Multiple Sclerosis

Study Medication Information
Nerispirdine 50, 100 and 200 mg tablets or matching placebo. Taken orally.

For more information, please contact Study Coordinator
Jennifer McAleenan
425-899-5371
jkmcaleenan@evergreenhealthcare.org

Study
Combi-RX

Principle Investigator
Theodore Brown, MD

Brief Description
A multi-center, double-blind, randomized study comparing the combined use of Interferon Beta-1a and Glatiramer Acetate to Interferon Beta 1  alone or Glatiramer Acetate alone in patients with Relapsing Remitting multiple sclerosis (CombiRX-Phase III).

For more information, please contact Study Coordinator
Shalom Kilcup
425-899-5369
sekilcup@evergreenhealthcare.org